Luis Kluth

Luis Kluth

Auto-generated profile, based on publicly available information

Luis Kluth

Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GBGazanfer Belge
Gazanfer Belge
CDCansu Dumlupinar
Cansu Dumlupinar
TNTim Nestler
Tim Nestler
MKMarkus Klemke
Markus Klemke
PTPeter Törzsök
Peter Törzsök
KDKlaus-Peter Dieckmann
Klaus-Peter Dieckmann
Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.

27 November 2014 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
Clemens Mathias RosenbaumClemens Mathias Rosenbaum
Clemens Mathias Rosenbaum
MSMarianne Schmid
Marianne Schmid
TLTim A. Ludwig
Tim A. Ludwig
LKLuis A. Kluth
Luis A. Kluth
PRPhilip Reiss
Philip Reiss
SASascha A. Ahyai
Sascha A. Ahyai

10 July 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
CSCarolin Siech
Carolin Siech
MAMario De Angelis
Mario De Angelis
LJLetizia Maria Ippolita Jannello
Letizia Maria Ippolita Jannello
Francesco Di BelloFrancesco Di Bello
Francesco Di Bello
NPNatali Rodriguez Penaranda
Natali Rodriguez Penaranda
PKPierre I. Karakiewicz
Pierre I. Karakiewicz
Background: To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes. Methods: Using the Surveillance, Epidemiology, and End Results database (2004–2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models. Results: Of 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all p < 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients. Conclusions: Compared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.


30 November 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
VZValentin Zumstein
Valentin Zumstein
RDRoland Dahlem
Roland Dahlem
VMValentin Maurer
Valentin Maurer
PMPhillip Marks
Phillip Marks
LKLuis A. Kluth
Luis A. Kluth
MVMalte W. Vetterlein
Malte W. Vetterlein

6 June 2014 in BJU International
Verified
Journal Article
Open access
PDF file
ILIlaria Lucca
Ilaria Lucca
MRMorgan Rouprêt
Morgan Rouprêt
LKLuis Kluth
Luis Kluth
Michael RinkMichael Rink
Michael Rink
DTDerya Tilki
Derya Tilki
Tobias KlatteTobias Klatte
Tobias Klatte
Objective: To compare outcomes of patients with lymph node ( LN )‐positive urothelial carcinoma of the bladder ( UCB ) treated with or without cisplatin‐based combined adjuvant chemotherapy ( AC ) after radical cystectomy ( RC ). Patients and Methods: We retrospectively analysed 1523 patients with LN ‐positive UCB , who underwent RC with bilateral pelvic LN dissection. All patients had no evidence of disease after RC . AC was administered within 3 months. Competing‐risks models were applied to compare UCB ‐related mortality. Results: Of the 1523 patients, 874 (57.4%) received AC . The cumulative 1‐, 2‐ and 5‐year UCB ‐related mortality rates for all patients were 16%, 36% and 56%, respectively. Administration of AC was associated with an 18% relative reduction in the risk of UCB ‐related death (subhazard ratio 0.82, P = 0.005). The absolute reduction in mortality was 3.5% at 5 years. The positive effect of AC was detectable in patients aged ≤70 years, in women, in pT3 –4 disease, and in those with a higher LN density and lymphovascular invasion. This study is limited by its retrospective and non‐randomised design, selection bias, the absence of central pathological review and lack in standardisation of LN dissection and cisplatin‐based protocols. Conclusion: AC seems to reduce UCB ‐related mortality in patients with LN ‐positive UCB after RC . Younger patients, women and those with high‐risk features such as pT3 –4 disease, a higher LN density and lymphovascular invasion appear to benefit most. Appropriately powered prospective randomised trials are necessary to confirm these findings.